PMID- 23383109
OWN - NLM
STAT- MEDLINE
DCOM- 20130722
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 1
DP  - 2013
TI  - The brominated compound aeroplysinin-1 inhibits proliferation and the expression 
      of key pro- inflammatory molecules in human endothelial and monocyte cells.
PG  - e55203
LID - 10.1371/journal.pone.0055203 [doi]
LID - e55203
AB  - Aeroplysinin-1 is a brominated antibiotic used by some sponges for defense 
      against bacterial pathogen invasion. Aeroplysinin-1 has a wide spectrum of 
      anti-tumoral action and behaves as a potent anti-angiogenic compound for bovine 
      aortic endothelial cells. In this study, we demonstrate anti-angiogenic effects 
      of aeroplysinin-1 on human endothelial cells. Furthermore, the response of 
      angiogenesis related genes to aeroplysinin-1 treatment was studied in human 
      endothelial cells by using gene arrays. The major changes were observed in 
      thrombospondin 1 (TSP-1) and monocyte chemoattractant protein-1 (MCP-1), both of 
      which were down-regulated. These inhibitory effects of aeroplysinin-1 were 
      confirmed by using independent experimental approaches. To have a deeper insight 
      on the anti-inflammatory effects of aeroplysinin-1 in endothelial cells, cytokine 
      arrays were also used. This experimental approach confirmed effects on MCP-1 and 
      TSP-1 and showed down-regulation of several other cytokines. Western blotting 
      experiments confirmed down-regulation of ELTD1 (EGF, latrophilin and seven 
      transmembrane domain-containing protein 1), interleukin 1alpha and matrix 
      metalloproteinase 1 (MMP-1). These results along with our observation of a 
      dramatic inhibitory effect of aeroplysinin-1 on cyclooxygenase-2 protein 
      expression levels in endothelial cells and a human monocyte cell line suggest 
      that aeroplysinin-1 could be a novel anti-inflammatory compound with potential 
      pharmacological interest.
FAU - Martinez-Poveda, Beatriz
AU  - Martinez-Poveda B
AD  - Department of Molecular Biology and Biochemistry, Faculty of Sciences, University 
      of Malaga, Malaga, Spain.
FAU - Garcia-Vilas, Javier A
AU  - Garcia-Vilas JA
FAU - Cardenas, Casimiro
AU  - Cardenas C
FAU - Melgarejo, Esther
AU  - Melgarejo E
FAU - Quesada, Ana R
AU  - Quesada AR
FAU - Medina, Miguel A
AU  - Medina MA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130128
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Acetonitriles)
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cyclohexenes)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Tetrazolium Salts)
RN  - 0 (Thiazoles)
RN  - 0 (Thrombospondin 1)
RN  - 28656-91-9 (aeroplysinin I)
RN  - EUY85H477I (thiazolyl blue)
SB  - IM
MH  - Acetonitriles/analysis/*pharmacology
MH  - Angiogenesis Inhibitors/*pharmacology
MH  - Animals
MH  - Cell Proliferation/*drug effects
MH  - Chemokine CCL2/metabolism
MH  - Cyclohexenes/analysis/*pharmacology
MH  - Cyclooxygenase 2 Inhibitors/pharmacology
MH  - Endothelial Cells/*metabolism
MH  - Gene Expression Regulation/*drug effects
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Monocytes/*metabolism
MH  - Porifera/*chemistry
MH  - Tetrazolium Salts
MH  - Thiazoles
MH  - Thrombospondin 1/metabolism
PMC - PMC3557235
COIS- Competing Interests: MAM is a PLOS ONE Editorial Board member. This does not 
      alter the authors' adherence to all the PLOS ONE policies on sharing data and 
      materials.
EDAT- 2013/02/06 06:00
MHDA- 2013/07/23 06:00
PMCR- 2013/01/28
CRDT- 2013/02/06 06:00
PHST- 2012/07/30 00:00 [received]
PHST- 2012/12/19 00:00 [accepted]
PHST- 2013/02/06 06:00 [entrez]
PHST- 2013/02/06 06:00 [pubmed]
PHST- 2013/07/23 06:00 [medline]
PHST- 2013/01/28 00:00 [pmc-release]
AID - PONE-D-12-22649 [pii]
AID - 10.1371/journal.pone.0055203 [doi]
PST - ppublish
SO  - PLoS One. 2013;8(1):e55203. doi: 10.1371/journal.pone.0055203. Epub 2013 Jan 28.